Previous 10 | Next 10 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET...
Aurinia Pharmaceuticals, Inc. (AUPH) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Glenn Schulman - Investor Relations Richard Glickman - Emeritus Chairman & Chief Executive Officer Peter Greenleaf - Chief Executive Officer Dennis Bourgeault ...
Aurinia Pharma (NASDAQ: AUPH ): Q1 GAAP EPS of -$0.14 beats by $0.01 . Revenue of $0.03M in-line (flat Y/Y). Cash and equivalents of $144.3M. Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,
- Conference call and webcast to be hosted today at 4:30pm EDT - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent op...
Market Assessment 2019 could be a transformational year for Aurinia Pharmaceuticals (AUPH) from being a clinical-stage small-cap ($573M) to commercial stage biopharma, if the ongoing Phase 3 study of voclosporin (formerly ISA247) in patients with lupus nephritis ((LN)) achieves its primary...
In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (the “Company”) a late clinical-stage biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today recognized World Lupus Day and Lu...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the co...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 8:30am PT (11:30am ET) in...
Aurinia Pharmaceuticals ( AUPH -2.9% ) appoints Peter Greenleaf as CEO of the company and Director More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...